| Literature DB >> 32412188 |
Muhammad Ilyas1, Sumera Afzal1, Jamshaid Ahmad1, Saad Alghamdi2, Muhammad Khurram3.
Abstract
Measles infection is of substantial interest to immunologists due to its paradoxical interaction with the immune system. After the acquisition of the measles infection, secondary infection plays a pivotal role in measles-related deaths. A cross-sectional study conducted between December 2018 and July 2019 is presented here. A total of one hundred children of both genders presented with measles complications were included following WHO criteria. Measles confirmation was done by quantitative determination of anti-measles antibodies (IgM) in patients' sera while patient-related demographic data, vaccination status, and other clinical information were obtained on a separate form. The number of female patients (52%) slightly exceeded the number of males (48%). 43% of patients' parents were illiterate, and half of the patients (50%) were from a poor background. The majority of children (76%) who presented with the complications did not receive a measles vaccine. 56% of children were breastfed while 58% received vitamin A supplements but developed complications. The elevated levels of anti-measles IgM were observed in 77% of cases. In both genders, the major complications were pneumonia, lower respiratory tract infection (LRTI), acute diarrhea, diarrhea and LRTI, pneumonia and diarrhea, otitis media and pneumonia, myocarditis and LRTI, and pneumothorax. The majority of the infected children (n = 48) under 12 months of age had associated complications. It has been observed that the measles virus strikes early age children in the northwestern region of Pakistan, which is an alarming situation and is associated with the aforementioned complications, especially in unvaccinated children. Anti-measles IgM is an important serological parameter for early diagnosis of measles infection. Measles infection is of substantial interest to immunologists due to its paradoxical interaction with the immune system. After the acquisition of the measles infection, secondary infection plays a pivotal role in measles-related deaths. A cross-sectional study conducted between December 2018 and July 2019 is presented here. A total of one hundred children of both genders presented with measles complications were included following WHO criteria. Measles confirmation was done by quantitative determination of anti-measles antibodies (IgM) in patients’ sera while patient-related demographic data, vaccination status, and other clinical information were obtained on a separate form. The number of female patients (52%) slightly exceeded the number of males (48%). 43% of patients’ parents were illiterate, and half of the patients (50%) were from a poor background. The majority of children (76%) who presented with the complications did not receive a measles vaccine. 56% of children were breastfed while 58% received vitamin A supplements but developed complications. The elevated levels of anti-measles IgM were observed in 77% of cases. In both genders, the major complications were pneumonia, lower respiratory tract infection (LRTI), acute diarrhea, diarrhea and LRTI, pneumonia and diarrhea, otitis media and pneumonia, myocarditis and LRTI, and pneumothorax. The majority of the infected children (n = 48) under 12 months of age had associated complications. It has been observed that the measles virus strikes early age children in the northwestern region of Pakistan, which is an alarming situation and is associated with the aforementioned complications, especially in unvaccinated children. Anti-measles IgM is an important serological parameter for early diagnosis of measles infection.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32412188 PMCID: PMC7324859 DOI: 10.33073/pjm-2020-020
Source DB: PubMed Journal: Pol J Microbiol ISSN: 1733-1331
Demographic and related data of the patients.
| Parameters | Patient |
|---|---|
|
| |
|
| 100 |
| Male | 48 (48%) |
| Female | 52 (52%) |
|
| |
| Male | 15.06 (± 9.42) |
| Female | 15.94 (± 9.42) |
|
| |
| Breastfeed | 56% |
| Formula feed | 32% |
| Breast + Formula | 12% |
|
| |
| Vaccinated (Total) | 24% |
| < 12 months | (n = 2) |
| 12–24 months | (n = 17) |
| > 24 months | (n = 5) |
| Unvaccinated (Total) | 76% |
| < 12 months | (n = 42) |
| 12–24 months | (n = 23) |
| > 24 months | (n = 11) |
|
| 58% |
|
| |
|
| |
| High (≥ $4,301 per annum) | 12% |
| Middle (≥ $1,701 and ≤ $4,300 per annum) | 38% |
| Lower (≤ $1,700 per annum) | 50% |
|
| |
| Higher | 7% |
| Secondary | 28% |
| Primary | 22% |
| Uneducated | 43% |
Fig. 1.The overall distribution of anti-measles antibody (IgM) in patients’ sera (n = 100).
Fig. 2.Gender distribution of measles complications (Percentage).
Frequency and distribution of measles complications in different age groups of patients
| Clinical complications | Age-wise distribution | |||
|---|---|---|---|---|
| < 12 months | 12–24 months | > 24 months | Total | |
| Pneumonia | 23 (47.9%) | 15 (37.5%) | 3 (25%) | 41 |
| LRTI | 8 (16.7) | 8 (20)% | 2 (16.7%) | 18 |
| Otitis media | – | 1 (2.5%) | 1 (8.3%) | 2 |
| Acute diarrhea | 4 (8.3%) | 1 (2.5%) | 1 (8.3%) | 6 |
| Diarrhea + LRTI[ | 6 (12.5%) | 8 (20%) | 3 (25%) | 17 |
| Pneumonia + Diarrhea | 3 (6.25%) | 2 (5%) | 1 (8.3%) | 6 |
| Otitis media + Pneumonia | 2 (4.1%) | 1 (2.5%) | 1 (8.3%) | 4 |
| Myocarditis + LRTI | 1 (2.0%) | 2 (5%) | – | 3 |
| SSPE[ | – | 1 (2.5%) | – | 1 |
| Pneumothorax | 1 (2.0%) | 1 (2.5%) | – | 2 |
| Total | 48 | 40 | 12 | 100 |
LRTI – Lower respiratory tract infection
SSPE – Subacute sclerosing panencephalitis
Fig. 4.Distribution of measles complications among measles-vaccinated and unvaccinated children.
Fig. 3.Number of confirmed measles cases from 2006 to 2019 in Pakistan (WHO 2019; updates).
Vaccination schedule for children in Pakistan.
| Age of vaccine administration | Name of vaccine |
|---|---|
| Immediate after birth | 1. BCG |
| 2. OPV | |
| 3. Hepatitis-B | |
| After 6 weeks | 1. OPV-1 |
| 2. Penta-1 | |
| 3. Pneumo-1 | |
| After 10 weeks | 1. OPV-2 |
| 2. Penta-2 | |
| 3. Pneumo-2 | |
| After 14 weeks | 1. OPV-3 |
| 2. Penta-3 | |
| 3. Pneumo-3 | |
| 4. IPV | |
| After 9 months | Measles-1 |
| After 15 months | Measles-2 |
http://www.epi.gov.pk/immunisation-schedule/